Beijing, China

Dongliang Mo


Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:


Years Active: 2025

where 'Filed Patents' based on already Granted Patents

1 patent (USPTO):

Title: Innovator Dongliang Mo: Pioneering Tumor Treatment Inventions

Introduction: Dongliang Mo, a talented inventor based in Beijing, China, has made significant strides in the field of pharmaceutical innovations. With a keen focus on developing solutions for tumor diseases, his work is paving the way for advanced treatment options. His contributions showcase the intersection of science and innovation, reflecting his commitment to improving healthcare outcomes.

Latest Patents: Dongliang Mo holds a patent for a SHP2 phosphatase allosteric inhibitor, which is notable for its potential application in tumor therapies. This patent encapsulates a specific structure designed for use in drug development, thus broadening the scope of treatment for various tumor-related conditions. The inhibitor, along with its optical isomer compound and pharmaceutically acceptable salts, is poised to play a vital role in future oncological treatments.

Career Highlights: As a member of Beijing Shenogen Pharma Group Ltd., Dongliang has positioned himself at the forefront of pharmaceutical research and development. His dedication and innovative thinking have allowed him to collaborate with esteemed colleagues, contributing to groundbreaking advancements in cancer therapy.

Collaborations: Dongliang Mo works alongside talented professionals such as Huting Wang and Lei Zhang. Their collaborative efforts demonstrate the power of teamwork in driving innovation within the industry. Together, they are focused on enhancing therapeutic applications and exploring new frontiers in medical treatments.

Conclusion: Dongliang Mo exemplifies the spirit of innovation through his dedication to advancing cancer treatments. His patent for a SHP2 phosphatase allosteric inhibitor underlines his commitment to finding effective solutions for challenging medical conditions. As he continues his work at Beijing Shenogen Pharma Group Ltd., the impact of his inventions is likely to resonate throughout the pharmaceutical landscape, offering hope to those affected by tumor diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…